Rights to 36,234 shares accompany options with a $2.76 exercise price awarded by Altimmune (ALT).
Altimmune's Principal Accounting Officer, Richard Thomas Menziuso, was awarded 84,546 stock options with a $2.76 exercise price and 36,234 restricted stock units on October 1, 2026. Both equity awards have a four-year vesting schedule, with 25% vesting on October 1, 2027, and the remainder vesting monthly for options and annually for RSUs, contingent on his continued service. This insider transaction highlights compensation practices and long-term incentives for key executives at Altimmune.
Altimmune Appoints Richard Menziuso as Principal Accounting Officer
Altimmune has appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. This move brings a seasoned finance executive with 28 years of experience to a critical accounting role. The company notes that there are no special arrangements or related-party transactions tied to this appointment, and Altimmune will enter into a standard indemnification agreement with Menziuso.
Altimmune appoints Richard Menziuso as VP, Global Controller and Principal Accounting Officer
Altimmune (ALT) has appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. Gregory Weaver will continue in his role as Chief Financial Officer. Menziuso brings 28 years of finance and accounting experience, including 12 years in public accounting and previous roles at several pharmaceutical and medical technology companies.
Tangible book value per share of Altimmune, Inc. – HAN:3G0
This article provides financial information for Altimmune, Inc. (HAN:3G0) from TradingView, specifically focusing on its tangible book value per share. It indicates the market status as closed with no trades and mentions the data sources used.
Non-operating income (total) of Altimmune, Inc. – HAN:3G0
This article provides financial data for Altimmune, Inc. (HAN:3G0) focusing specifically on its non-operating income. The data is sourced from ICE Data Services and FactSet, with SEC filings provided by Quartr. It appears to be a snapshot from a financial data platform.
Form 8K Altimmune Inc For: 29 September By Investing.com
This article reports on an SEC Form 8K filing by Altimmune Inc. for September 29. The filing pertains to financial markets and is published by Investing.com, a platform for global financial news and data. The content is brief, primarily serving as an announcement of the filing's availability.
Altimmune appoints Richard Menziuso as vice president and principal accounting officer
Altimmune, Inc. (NASDAQ:ALT) has announced the appointment of Richard Menziuso as vice president, global controller, and principal accounting officer, effective Tuesday. Menziuso brings 28 years of finance and accounting experience, having previously served at Centessa Pharmaceuticals, Thermo Fisher Scientific, and Axovant Gene Therapies. This move follows Altimmune's recent Q2 earnings report, which indicated a narrower-than-expected loss and a strong cash balance of $519 million, as the company progresses with late-stage trials for liver disease and alcohol use disorder.
Form 8K Altimmune Inc For: 29 September By Investing.com
The article reports on Altimmune Inc.'s Form 8K filing for September 29, 2026. This brief piece, published by Investing.com, indicates a routine regulatory disclosure without providing specific details of the filing's content.
Altimmune to Participate in Stifel Cardiometabolic Forum
Altimmune, Inc. announced its management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026, at 10:30 a.m. ET. The company, a late clinical-stage biopharmaceutical firm, is developing pemvidutide for serious liver diseases, including MASH, AUD, and ALD. A webcast of the chat will be available on Altimmune's website.
Altimmune to Participate in Stifel Cardiometabolic Forum
Altimmune, Inc. announced its participation in the Stifel 2026 Virtual Cardiometabolic Forum, where management will engage in a fireside chat on September 30, 2026, at 10:30 a.m. ET. The company is a late clinical-stage biopharmaceutical firm focused on developing pemvidutide for serious liver diseases, including MASH, AUD, and ALD. A webcast of the event will be available on Altimmune's website.
Altimmune (ALT) exec gains stock as 24,000 RSUs vest
Altimmune's Chief Commercial Officer, Linda M. Richardson, had 24,000 Restricted Stock Units (RSUs) vest into common stock on September 16, 2026. A portion of these shares, 6,826, were withheld to cover taxes associated with the vesting. After this transaction, Richardson still holds 72,000 RSUs, which will vest over the next three years.
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Altimmune (ALT) shares have risen 14.2% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q2 2026 loss of 12 cents per share, with no revenues as it lacks a marketed drug. R&D expenses increased due to clinical studies for pemvidutide, and the company expects its cash runway to last until 2029.
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune, Inc. announced that its management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. The company is a late clinical-stage biopharmaceutical firm focused on developing therapies for serious liver diseases, with its lead candidate, pemvidutide, targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). A webcast of the fireside chat will be available on Altimmune's website.
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune, Inc. announced its management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 9:30 a.m. ET. The company, a late clinical-stage biopharmaceutical firm, is developing pemvidutide for serious liver diseases, including MASH, AUD, and ALD. A webcast of the event will be available on the Altimmune website.
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune, Inc. announced its management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. The biopharmaceutical company is developing pemvidutide for serious liver diseases like MASH, AUD, and ALD. A webcast of the event will be available on the company's website.
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Altimmune, Inc. announced its management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, at 9:30 a.m. ET. The company is a late clinical-stage biopharmaceutical firm focusing on serious liver diseases with its lead candidate, pemvidutide. A webcast of the event will be available on Altimmune's website.
Altimmune (NASDAQ:ALT) Trading Up 9.2% - Should You Buy?
Altimmune (NASDAQ:ALT) shares rose 9.2% on Friday, closing at $3.22, although trading volume was significantly lower than average. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and a $14.33 average price target. Despite beating quarterly loss estimates, the clinical-stage biopharmaceutical company continues to face deeply negative profitability metrics, with institutional investors holding 78.05% of its stock.
Altimmune Inc (ALT) News, Articles, Events & Latest Updates
This page compiles recent news and updates for Altimmune Inc (ALT), focusing on its financial performance and pipeline developments. Key articles discuss ALT's cash position supporting its pemvidutide programs for MASH, AUD, and ALD, the progression of pemvidutide into Phase III MASH testing with data expected in 2029, and the company's Q2 earnings report highlighting a narrower-than-expected loss and extended cash runway.
HC Wainwright Estimates Altimmune's Q3 Earnings (NASDAQ:ALT)
HC Wainwright has revised its Q3 2026 earnings per share estimates for Altimmune (NASDAQ:ALT) to a loss of $0.13, an improvement from its prior estimate of $0.15. The firm also updated its full-year and multi-year forecasts, expecting the company to remain unprofitable through 2030, though with reduced projected losses. Altimmune recently surpassed consensus estimates for its latest quarter, reporting a loss of $0.12 per share against an expected $0.14 loss.
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
Altimmune (ALT) has a growing cash position, now at $519 million, which is expected to fund operations into 2029 and support its phase III MASH program and phase II ALD study. The company's valuation reflects its reliance on the single experimental drug, pemvidutide, for various metabolic conditions, but it faces significant execution, competitive, and long-term funding risks, leading to a Zacks Rank #3 (Hold) despite its improved cash runway.
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright has reiterated its Buy rating for Altimmune (ALT.US), maintaining a target price of $20. This indicates the firm's continued confidence in the company's stock performance.
Altimmune Stock Price Forecast. Should You Buy ALT?
Altimmune, Inc. (ALT) is currently rated as a "Sell Candidate" by StockInvest.us, despite a recent 2.08% gain. The stock shows both buy signals from a pivot bottom and MACD, alongside sell signals from short and long-term Moving Averages, indicating mixed short-term prospects. With a projected 5.38% rise over the next three months, the analysis suggests a negative evaluation for the stock in the immediate future.
Altimmune (ALT) deepens Q2 2026 loss while pemvidutide liver trials reach key milestones
Altimmune (ALT) reported a Q2 2026 net loss of $22.8 million and a six-month net loss of $45.4 million, with no revenue generated. Despite the increased losses and share dilution, the company highlighted significant progress in its pemvidutide liver trials, including initiating a Phase 3 MASH trial, reporting positive Phase 2 AUD data, and completing enrollment for a Phase 2 ALD trial. Altimmune maintains a strong cash position of $519 million to fund ongoing clinical developments.
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares
Altimmune Inc.'s President and CEO, Jerome Durso, recently purchased 15,000 shares of the company's stock, increasing his direct ownership to 62,500 shares. This transaction is part of a larger trend of insider buying at Altimmune, with 11 insider buys and no sells in the past year, signaling strong confidence from leadership in the company's future, particularly its focus on obesity and liver disease treatments. The purchase, valued at $44,250, suggests insiders believe the stock is undervalued despite the risks inherent in a clinical-stage biopharmaceutical company.
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each
Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, purchased 15,000 shares of the company's common stock at $2.95 per share on August 13, 2026. This transaction, conducted in the open market or a private transaction, increased his direct holdings to 62,500 shares. The Form 4 filing indicates the purchase was not made under a Rule 10b5-1 trading plan.
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune (ALT) reported a Q2 2026 loss of 12 cents per share, which was narrower than the Zacks Consensus Estimate of 15 cents. The company's lead candidate, Pemvidutide, a dual glucagon/GLP-1 receptor agonist, is progressing through late-stage clinical trials for MASH, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Altimmune expects its cash reserves to fund operations until 2029.
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune (ALT) reported a narrower-than-expected loss of 12 cents per share in Q2 2026, beating the Zacks Consensus Estimate of 15 cents. The company, which currently has no marketed drugs, focused on advancing its lead candidate, pemvidutide, with ongoing clinical studies for MASH, AUD, and ALD, and expects its cash runway to extend into 2029. Shares of ALT have declined by 18.9% year-to-date.
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary
Altimmune, Inc. reported its second-quarter 2026 results, showing no revenue and a net loss of $(22.83M), with diluted loss per share at $(0.12). This represents an improvement in EPS compared to $(0.27) in Q2 2025. Key business highlights include the start of the PERFORMA Phase 3 MASH trial, positive IMPACT MASH data, successful RECLAIM Phase 2 AUD results, and a headquarters relocation to Morristown, NJ.
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT
Dimensional Fund Advisors LP significantly increased its stake in Altimmune, Inc. by 268.7% during the first quarter, acquiring an additional 762,223 shares to own a total of 1.05 million shares valued at $3.22 million. Other institutional investors also adjusted their positions in Altimmune, which currently has 78.05% institutional ownership. Despite recent stock performance near its 52-week low and ongoing negative profitability, analysts maintain a "Moderate Buy" rating with a consensus price target of $14.33.
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results
Altimmune Inc (ALT) reported Q2 '26 earnings with an EPS of -$0.12, beating the estimated -$0.14 by 11.44%. The company achieved significant clinical milestones, including initiating a Phase 3 MASH trial and positive Phase 2 results in AUD, while also advancing enrollment for its ALD development program. However, Altimmune experienced an increased net loss and higher research and development expenses during the quarter.
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune announced its Q2 2026 financial results, highlighting key progress in its clinical programs for pemvidutide. The company initiated a global Phase 3 trial for MASH, reported positive topline data from a Phase 2 AUD trial, and completed enrollment for a Phase 2 ALD trial. Altimmune reported $519 million in cash and cash equivalents, with a net loss of $22.8 million for the quarter.
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Altimmune (NASDAQ:ALT) reported quarterly earnings, beating analyst expectations with a loss of $0.12 per share against an anticipated loss of $0.14. The company announced progress in its pemvidutide programs, including the start of the Phase III MASH trial and positive results from the Phase II alcohol use disorder study. Altimmune holds approximately $519 million in cash, sufficient to fund the MASH trial's 52-week readout, and plans to seek non-dilutive financing for potential future programs.
William Blair Maintains Altimmune(ALT.US) With Hold Rating
William Blair has reiterated its Hold rating on Altimmune (ALT.US). This indicates that the analyst firm recommends investors maintain their current position in the stock, without suggesting buying more or selling. The article does not provide specific reasons or financial data behind this rating.
Altimmune Releases Q2 2026 Financial Results
Altimmune, Inc. (ALT) announced its Q2 2026 financial results, reporting a narrower basic and diluted loss of $0.12 per share compared to the -$0.14 expected loss. The company posted $0 in revenue for the quarter, a 100% decrease from Q2 2025, and a net loss of $22.8 million. Wall Street analysts currently rate Altimmune with 9 buy, 2 hold, and 0 sell recommendations.
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise
Altimmune reported a narrower-than-expected Q2 2026 loss of $0.12 per share, beating analyst estimates, as the biotech advanced late-stage trials for liver disease and alcohol use disorder. The company's shares rose 3.87% following the announcement. Altimmune highlighted a strong cash position of $519 million, sufficient to fund operations through the 2029 MASH data readout, and positive phase II data from its alcohol use disorder study, RECLAIM.
Altimmune Q2 Earnings Call Highlights
Altimmune has initiated patient enrollment for its Phase III PERFORMA trial of pemvidutide for MASH and is advancing plans for later-stage development in AUD. The company reported positive topline results from its Phase II RECLAIM trial in AUD and completed enrollment for the Phase II RESTORE trial in ALD. Altimmune ended Q2 with $519 million in cash, which is expected to fund operations through the PERFORMA 52-week data readout in 2029, with a preference for non-dilutive financing for a potential Phase III AUD trial.
Altimmune posts $22.8M Q2 net loss, $519M cash; advances pemvidutide Phase 3 and Phase 2 programs
Altimmune reported a net loss of $22.8 million and held $519 million in cash for Q2 2026. The company highlighted significant progress in its pemvidutide programs, including the initiation of the PERFORMA Phase 3 MASH trial, positive topline results from the RECLAIM Phase 2 AUD trial, and completion of enrollment for the RESTORE Phase 2 ALD trial. Altimmune also completed a public offering raising $225 million and plans to relocate its headquarters.
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune, Inc. announced its second-quarter 2026 financial results, highlighting key milestones including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial. The company also completed patient enrollment for the RESTORE Phase 2 ALD trial, demonstrating progress in its pemvidutide development for serious liver diseases. Financially, Altimmune reported $519 million in cash, cash equivalents, and investments as of June 30, 2026, with a net loss of $22.8 million for the quarter.
Altimmune, Inc. (ALT) options chain – Yahoo Finance
This article displays the options chain for Altimmune, Inc. (ALT) as of August 7, 2026. It includes detailed call and put option data such as strike prices, last prices, changes, volume, and open interest for August 21, 2026, expiry. The current stock price and related tickers are also provided.
Altimmune to discuss its liver-treatment candidate Aug. 12
Altimmune (Nasdaq: ALT) will report its second quarter 2026 financial results on Wednesday, August 12, 2026, including a conference call and webcast at 8:30 a.m. ET to review results and provide a business update. The company is a late clinical-stage biopharmaceutical company developing pemvidutide for serious liver diseases such as MASH, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Following this announcement, Altimmune's stock (ALT) saw a mild negative market reaction, declining by 1.65%.
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Altimmune, Inc. (Nasdaq: ALT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 12, 2026. Management will host a conference call at 8:30 a.m. ET to discuss the results and update, which will also be webcast live on the company's Investor Relations website. Altimmune is a biopharmaceutical company developing pemvidutide for serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
Altimmune (ALT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ALT
This article provides a comprehensive overview of Altimmune's FDA-related activities for its drug pemvidutide, detailing clinical trial updates, regulatory submissions, and designations through 2026. Pemvidutide is being developed for conditions including obesity, MASH (metabolic dysfunction-associated steatohepatitis),
Altimmune (ALT) CFO acquires 1,753 shares via employee stock purchase plan
Altimmune, Inc. (ALT) CFO Gregory L. Weaver acquired 1,753 shares of common stock on July 31, 2026, through the company's 2019 Employee Stock Purchase Plan (ESPP). The shares were purchased at $2.414 each, representing 85% of the closing price on that day, for the ESPP period from February 1 to July 31, 2026. Following this transaction, Weaver directly holds 39,831 shares of Altimmune common stock.
Altimmune Initiates PERFORMA Phase 3 Trial Of Pemvidutide In Patients With Mash
Altimmune has announced the initiation of its PERFORMA Phase 3 trial for pemvidutide. This trial focuses on evaluating the drug's efficacy in patients diagnosed with MASH (Metabolic Dysfunction-Associated Steatohepatitis). The information was released via Reuters and is available on TradingView.
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Altimmune has begun enrolling patients in its global PERFORMA Phase 3 trial for pemvidutide, a dual glucagon/GLP-1 receptor agonist, to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis. The trial aims to evaluate the drug's efficacy and safety, with primary endpoints including fibrosis improvement and MASH resolution, following positive results from the IMPACT Phase 2b study. Anticipating 52-week data in 2029, this milestone advances Altimmune's lead program, which has also received FDA Fast Track and Breakthrough Therapy Designations for MASH.
Altimmune Inc Today's Market Trends | ALT Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey
This article provides a detailed analysis of Altimmune Inc (ALT) stock, highlighting its market trends, real-time quotes, and trading strategies. It covers key financial figures, institutional ownership, analyst ratings, and the company's biopharmaceutical pipeline, including pemvidutide for obesity and MASH. Despite recent stock performance, the company's fundamentals are considered healthy with high growth potential, and analysts rate it as a Buy with a significant upside.
H.C. Wainwright reiterates Altimmune stock rating on trial results
H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for Altimmune (NASDAQ:ALT) following positive Phase 2 trial results for its drug candidate, pemvidutide, in treating alcohol use disorder. The drug met its primary endpoint by significantly reducing heavy drinking days and also achieved FDA-recognized secondary endpoints. Altimmune plans to meet with the FDA regarding alcohol use disorder, complete enrollment for another relevant trial in Q3 2026, and start a Phase 3 trial for metabolic dysfunction-associated steatohepatitis also in Q3 2026.
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript
This article provides the transcript for Altimmune Inc.'s RECLAIM Phase 2 Trial in AUD Topline Results Conference Call held on July 28, 2026. The call began with an introduction by Louis Sine, Vice President of Investor Relations, and detailed how participants could ask questions. It focuses on the topline results of their Phase 2 trial for Alcohol Use Disorder.
Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide
Altimmune's stock surged in premarket trading following positive results from its Phase 2 MOMENTUM trial for pemvidutide, a GLP-1/glucagon receptor dual agonist. The trial met its primary and key secondary endpoints, showing significant weight loss at 48 weeks, with 75% of patients on the highest dose achieving at least 15% weight loss. Pemvidutide also demonstrated favorable safety and tolerability, with low rates of gastrointestinal side effects.
Altimmune Scores Alcohol Use Disorder Win As Lilly, Novo Circle Same Indication
Altimmune has achieved a significant milestone in treating alcohol use disorder, a field also being explored by major pharmaceutical companies like Eli Lilly and Novo Nordisk. The article highlights Altimmune's efforts to innovate the treatment paradigm for this condition.
